The euro area’s top stock benchmark is welcoming a rare entry by a biotech firm, promising to ignite fresh interest in a ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $6.00, and a low estimate of $4.00. Witnessing a positive shift, the current average ...

DAVIS, CALIF. — Scientists at the University of California, Davis, have developed wheat plants that stimulate production of its own fertilizer, which could bring environmental and cost-reduction ...

Marvell Technologies stock tumbled on Friday after a disappointing earnings report. The company reported light data-center revenue, and its sales forecast missed estimates. Analysts are worried that ...